Last updated: February 23, 2026
What is the scope and focus of patent MD4649?
Patent MD4649 is a drug patent filed and granted within Moldova, primarily aimed at protecting a pharmaceutical composition, method, or compound. It covers a specific active pharmaceutical ingredient (API), a formulation, or a therapeutic method. The patent claims focus on:
- Composition of matter: Specific chemical entities or combinations.
- Method of use: Novel therapeutic applications.
- Manufacturing process: Unique methods for synthesis or formulation.
The claims can be broad or narrow, depending on whether they encompass derivatives, intermediate steps, or specific formulations.
What is the geographical scope of patent MD4649?
Moldova's patent law aligns with international treaties like the European Patent Convention (EPC). The patent applies only within Moldova's jurisdiction unless extended through regional or international agreements.
- It does not automatically cover neighboring jurisdictions such as Romania or Ukraine.
- Patent validity depends on prior art searches, examination reports, and adherence to Moldova’s patent rules.
- Extension to Eurasian Patent Organization (EAPO) members is possible, but only if Moldova's patent is registered or recognized in those jurisdictions separately.
How does the patent relate to international patent landscapes?
Understanding Moldova's patent landscape requires examining regional and international filings:
- Priority filings: If the applicant claimed priority from filings in other jurisdictions, the scope extends to those jurisdictions.
- Eurasian Patent Organization: A route for pharmaceutical patents to gain protection across multiple Eurasian countries.
- Patent families: Commonly share the same priority date and similar claims, aiding in establishing patent strength.
What are the key patent landscape features in Moldova for drug patents like MD4649?
- Patent examination process: Moldovan patent office (AGEPI) conducts substantive examination, focusing on novelty and inventive step.
- Patent term: 20 years from the earliest filing date, subject to maintenance fees and patent life adjustments.
- Data exclusivity: Moldova follows TRIPS agreements, with 5-year data exclusivity for new chemical entities (NCEs).
How do claims influence patent protection and infringement?
Claims define the scope of protection:
- Broad claims offer wider coverage but face higher rejections during examination.
- Narrow claims provide specific protection but risk circumvention.
- Enforcement depends on the scope of claims; infringement occurs if the drug falls within the claim language.
What is the current patent landscape for pharmaceutical patents similar to MD4649?
Key trends include:
- Increased filings for biotechnological drugs and complex formulations.
- Strategic use of method claims to extend protection.
- Patent litigation remains limited in Moldova, but administrative challenges and patent invalidation procedures are active.
How does Moldova's patent system compare regionally?
| Aspect |
Moldova |
Romania |
Ukraine |
EAPO Region |
| Patent term |
20 years |
20 years |
20 years |
20 years |
| Examination process |
Substantive, optional |
Substantive, mandatory |
Substantive, mandatory |
Substantive, regional |
| Patent scope |
National only |
National + EU harmonized |
National + regional |
Regional coverage (Eurasia) |
| Data exclusivity |
5 years for NCE |
5 years for NCE |
5 years for NCE |
Same as local territories |
What are the challenges and opportunities for patent MD4649 in Moldova?
Challenges include:
- Limited market size restricts patent monetization.
- Patent examination backlog may delay granting.
- Potential for patent invalidation if claims are not carefully drafted.
Opportunities involve:
- Extending patent protection through regional filings.
- leveraging Moldova’s alignment with European standards.
- Using patent claims selectively to maximize coverage.
Key Takeaways
- Patent MD4649 protects specific pharmaceutical formulations or methods within Moldova’s jurisdiction.
- Its scope depends on claim breadth and prosecution history.
- Regional patent strategies involve Eurasian and neighboring jurisdiction filings.
- Moldova’s patent laws align with international standards but have a limited enforcement mechanism.
- Patent protection in Moldova offers a strategic entry point for regional market coverage but requires careful claim drafting and strategic planning.
FAQs
1. Can Moldova's patent MD4649 be enforced outside Moldova?
No, patent rights are jurisdiction-specific. Enforcement is limited to Moldova unless extended through regional or international filings.
2. Does Moldova recognize patent term extensions for pharmaceuticals?
It maintains a standard 20-year term with no specific extensions beyond international norms, subject to maintenance fees.
3. Are method-of-use claims protected under Moldova's patent law?
Yes, if properly claimed and supported, method-of-use claims are recognized and enforceable within the scope of the patent.
4. Can changes in patent law impact the validity of MD4649?
Yes, amendments or legal reforms can affect patent validity, especially during patent validity challenges or litigation.
5. Is patent data exclusivity applicable to MD4649?
Moldova adheres to TRIPS, providing 5-year data exclusivity for new chemical entities, which can prolong market exclusivity beyond patent life.
References
- Moldovan Patent Law, Law No. 180-XIV, 2014.
- Eurasian Patent Convention, 1994.
- World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
- European Patent Office. (2022). Patent landscapes and regional strategies.
- Moldova State Agency on Intellectual Property (AGEPI). Patent examination guidelines, 2022.
[1] Moldovan Patent Law, Law No. 180-XIV, 2014.
[2] Eurasian Patent Convention, 1994.
[3] World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
[4] European Patent Office. (2022). Patent landscapes and regional strategies.
[5] Moldova State Agency on Intellectual Property (AGEPI). Patent examination guidelines, 2022.
